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Lung stereotactic ablative radiotherapy (SABR) has recently become more common in the management of patients
with early-stage non-small cell lung cancer (NSCLC) and metastatic lung lesions who are not surgical candidates. By
design, SABR is applied to small treatment volumes, using fewer but significantly higher dose fractions, and steep
dose gradients. This treatment theoretically maximizes tumor cell death and decreases the risk of damage to the
surrounding normal tissues. Local control rates for SABR in early stage lung cancer remain high. Since the numbers
of primary tumor recurrences is small, some debate exists as to the appropriate definition of treatment failure.
Controversies remain regarding the most appropriate interpretation of imaging tests obtained to evaluate
treatment outcomes after lung SABR. Most definitions of progression include an increasing diameter of target lesion
which can be problematic given the known mass-like consolidation seen on CT imaging after ablative therapy.
Here, we present a case report illustrative of the pitfalls of relying solely on anatomic imaging to determine SABR
treatment failure.
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The use of stereotactic ablative radiotherapy (SABR) has
recently become more common in the management of
patients with early-stage non-small cell lung cancer
(NSCLC) and metastatic lung lesions who are not surgical
candidates. Although the use of SABR continues to in-
crease, controversies remain regarding the most appropri-
ate interpretation of imaging tests obtained to evaluate
treatment outcomes. Mass-like consolidation within the
lung parenchyma after SABR can often mimic tumor pro-
gression making evaluation of patient outcomes difficult
[1,2]. Likewise, the presence of FDG-avidity within the
lung at the site of previous SABR can be due to lung in-
flammation or pneumonitis versus tumor progression [3].
Currently adopted standards to define treatment failure
can often be contradictory in their use for defining disease
progression [4-6]. The current case illustrates the need
for a circumspect approach to imaging obtained after* Correspondence: mstauder@mdanderson.org
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reproduction in any medium, provided the orSABR and the utility of when to define tumor/disease
progression.Case description
A 70-year old male presented to our clinic after a chest
computed tomography (CT) scan revealed a speculated
mass in the anteriomedial portion of the left upper lobe of
the lung. A review of the patient’s imaging studies from 1
year prior shows the speculated mass to be a new finding.
The patient’s past medical history consisted of severe car-
diopulmonary disease, end stage emphysema, aortic sten-
osis, prior myocardial infarction, advanced peripheral
vascular disease and history of coronary artery bypass
graft. The patient is a current smoker and reported a 90
pack-year history of cigarette smoking. He required 3
liters/minute of oxygen by nasal cannula 24-hours per
day. The patient was registered in a prospective, IRB-
approved registry designed to collect pertinent clinical,
pathologic and treatment data on those patients receiving
SABR at Mayo Clinic.
A fluorine-18 [18F] FDG Positron Emission Tomog-
raphy (PET)/CT scan was performed for the purpose ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(SUV maximum 12.3) in the left upper lobe abutting the
mediastinum (Figure 1). Radiologic report stated the
nodule was worrisome for primary bronchogenic car-
cinoma. No evidence of FDG-avid metastatic disease
was seen. Consultation by medical oncology, thoracic
surgery and radiation oncology was obtained and due to
his significant comorbidities, surgical resection was
contraindicated. Likewise, due to poor pulmonary func-
tion, location of the lesion, and very high likelihood of
malignancy, a biopsy of the FDG-avid lesion was not
performed. Pulmonary function testing performed at
diagnosis revealed a FEV1 of 0.74 (21% of predicted)
with a DLCO of 39% predicted. Ultimately, the patient
elected to be treated with SABR for definitive manage-
ment of this FDG-avid presumed malignancy.
Treatment
The patient received SABR to a total dose of 48 Gray in
4 consecutive daily fractions (Fx). Treatment planning
was performed with full body immobilization and 4-
dimensional CT-based planning and daily cone-beam
CT (CBCT) for image guidance. Since January 2008, a
total of 372 patients have been treated with lung SABR
and our institutional technique has been described pre-
viously [7]. Briefly, each patient was immobilized using
the Body-Fix whole-body immobilization system (Elekta,
Stockholm, Sweden). Axial CT images were obtained on
a General Electric Light Speed RT 16-slice CT simulator
(GE Medical, Milwaukee, WI). Image acquisition was
obtained at a 2.5-mm slice thickness. Four-dimensional
CT imaging with respiratory monitoring was performed
using Varian RPM (Palo Alto, CA) and an infrared re-
flector that was placed on the patient’s chest or upper
abdomen. The patient’s respiratory pattern and CT data
were linked by respiratory phase at the time of simula-
tion. No abdominal compression was used. A treatment
isocenter was established on the average CT data set on
the GE Advantage virtual simulation station and normal
tissue and tumor volume contouring was performed on
the Advantage workstation. Fusion of the PET/CT dataFigure 1 Chest CT and PET scan of a 70 year-old male revealed a 3.3set from the patient’s staging study was used for assist-
ance in tumor delineation. A gross tumor volume
(GTV) of 7.9 cubic centimeters (cc) was defined using
CT lung windows (1500, -500). An internal target vol-
ume (ITV) of 10.3 cc was created from the gross tumor
volume, accounting for the movement of the tumor in
three dimensions using the four-dimensional CT image
data. The planning target volume (PTV) of 45 cc was
created by a uniform 0.5 cm expansion of the ITV in the
axially and 1.0 cm longitudinally. Normal tissue organs
at risk, including the spinal cord, heart, skin, chest wall,
heart, bronchial tree (including trachea), and esophagus
were defined and dose constraints similar to TG 101
were used [8]. A total of 99.4% of the PTV received at
least 48 Gy. Maximum PTV point dose was 6576 cGy
(137%) and the mean dose to the PTV was 5645 cGy.
The total lung received a mean dose of 350 cGy with
mean dose to the left lung of 370 cGy and 326 Gy to
theright lung. The conformality parameters for the treat-
ment were 2917 cGy (61%), 4.23, and 1.13 for D2cm, R50
and R100, respectively. Prior to each treatment an initial
CBCT scan was acquired, and a visual match performed.
The prescribed treatment was delivered uneventfully and
no acute treatment related side effects were observed.Follow-up
The patient returned to clinic approximately 2 months
after completing SABR and a CT scan of the chest (2.5
mm slice thickness) showed significant reduction in size
of the treated lung lesion without radiologic or clinical
evidence of radiation pneumonits (Figure 2). The patient
reported no changes in his baseline dyspnea and contin-
ued on 3 liters oxygen by nasal cannula. At 12 months
post-SABR, a CT scan of the chest revealed an increase
in size of the target lesion to 9 mmwith 2–3 mm of
growth since the scan obtained 6 months prior. Due to
the small change in size the decision was made to
continue close observation. Three additional CT scans
obtained at 3 month intervals showed no further in-
crease in the size of the lesion.cm hypermetabolic mass with an SUV maximum of 12.3.
Figure 2 CT scan performed 2 months after SABR shows
significant reduction in size of the treated lung lesion without
evidence of radiation pneumonits.
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cm nodule area within the previous treatment field. A
PET scan was performed for further assessment and
showed the nodule to be PET avid with a SUVmax of 5.2
(Figure 3). Also seen were new scattered small bilateral
pulmonary nodules too small to evaluate with PET and a
9 mm anterior right LL nodule (not in the treatment
field) which was not PET avid. The physicians involved
in the patient’s care felt this new nodule represented
local recurrence and the use of repeat SABR was
entertained. As repeat SABR in an oxygen dependent
patient was felt to be associated with significant risk
the patient was counselled to undergo biopsy. A
transbronchial biopsy was performed under the direc-
tion of pulmonary medicine. Pathologic review showed
benign bronchial mucosa and bronchial wall with
marked acute and chronic inflammation with bronchial
washings showing scant cellularity but no evidence of
malignancy. No further treatment was undertaken.
Three months after the biopsy, the maximal SUV di-
minished to 2.8 and the associated soft tissueFigure 3 Follow-up CT scan at 30 months post-treatment revealed a 2.5component had decreased in size measuring 1.5 cm.
The previously identified 9 mm right lower lobe pul-
monary nodule spontaneously resolved. There was no
evidence of other pulmonary nodules or metastatic dis-
ease. With continued follow up, the biopsied nodule
continued to decrease in size. The patient continues to
do well at 46-months of follow-up, with complete reso-
lution of the biopsied lesion on PET imaging (Figure 4).
No evidence of new pulmonary lesions and no other
changes in clinical status were noted. While some
consolidative mass remains at 46 months, negative bi-
opsy and the loss of FDG avidity within the lesion de-
note stable disease without evidence of recurrence.Discussion
The presented case report documents the apparent
treatment failure by radiologic criteria of an early stage
NSCLC after SABR. A negative biopsy of the target
lesion and a total follow-up of 46 months indicate
tumor pseudoprogression with no evidence of recurrent
disease.
Local control rates after treatment with SABR for early
stage lung cancer have been reported to be as high as
80-100% [9-13]. Since the numbers of primary tumor re-
currences remain small, some debate exists as to the ap-
propriate definition of treatment failure. Ongoing lung
SABR clinical trials employ the RECIST criteria to assess
target lesion response to treatment which defines pro-
gressive disease by two criteria 1) an increase in the total
length of all measurable lesions of more than 20% (and
at least 5 mm) compared with the smallest sum of lesion
sizes or 2) the appearance of unequivocal new disease
[4]. In addition to anatomical imaging such as CT and
MRI, PET scan data can also be used in tumors with cri-
teria meeting local enlargement (LE) status to help de-
termine progression. Current RTOG trials state that a
lesion should be avid on (PET)imaging with uptake of a
similar intensity as the pre-treatment staging, but given
the long interval history from treatment in our patient,
this definition becomes problematic [14].× 1.9 cm nodule in the previous treatment field with a SUVmax of 5.2.
Figure 4 CT scan at 46-months of follow-up with residual
consolidative mass at the site of the biopsied lesion.
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FDG tumor standard uptake value (SUV) of greater
than 25% within the tumor region is termed progressive
metabolic disease (PMD) [6], but no temporal relation
is defined. Also, both the RECIST and EORTC defini-
tions can be limited in the face of newer ablative radi-
ation techniques such as SABR which may produce
profound local inflammatory responses. As a result, at-
tempts to better define the PET criteria of treatment
failure have recently been initiated. In the recently de-
scribed PERCIST 1.0 model, metabolic progression is
defined as a 30% increase in theSUV corrected for lean
body mass, new [18F]FDG–avid lesions, or growth in le-
sion total glycolysisby more than 75% [5]. The lesion
described in this case report, by either RECIST 1.1 or
PERCIST 1.0 criteria, would be categorized as a partial
response (PR) in the post therapy setting and subse-
quently as progressive disease (PD) by RECIST or as
progressive metabolic disease (PMD).
In general, the SUVmax measured on post-SABR PET
imaging decreases in a linear fashion. This is shown in
one recent study analyzing the SUV before and after
SABR in patients with early stage NSCLC [15]. Prior to
SABR, the 14 patients evaluated in this pilot study had a
median SUV of 8.7 with 6 of 13 maintaining a persistent
SUVmax> 3.5 at 12 months post-treatment. Recently, au-
thors from MD Anderson Cancer Center reported on
the use of PET to assess local failure after lung SABR
[3]. In the 128 patients evaluated, a cut-off of SUV max
of 5.0 was found to have 100% sensitivity and 91% speci-
ficity for tumor recurrence. Additionally, the negative
predictive value if obtained at least 6 months after treat-
ment was 100%.
Our patient is unique in that near complete response
was seen on post treatment CT scans and all PET scanswithin the first 30 months after treatment were unre-
markable for any FDG-avid lesions suggesting progres-
sion of disease. Another recent study of 80 patients
receiving SABR for early-stage peripheral NSCLC re-
ports that the median latency time for developing a
mass-like consolidation in the area of treatment was 7
and 12 months in patients with and without tumor re-
currence, respectively. Additionally, in all patients with
tumor recurrence, consecutive rises in the volume of
mass-like consolidation on serial imaging at 3-month in-
tervals was seen [16]. The development of consolidation
seen on CT scan may occur in 68-74% of patients receiv-
ing lung SABR, but only 11-30% truly represent recur-
rent tumor [1,2].
Given the typically short timeframe to recurrence
seen after lung SABR as well as the high incidence of
mass-like consolidation seen on follow-up imaging, one
could potentially propose a new definition for tumor
progression. Since tumor progression after SABR is an
uncommon phenomenon and salvage treatment options
are usually limited and associated with progressive risk,
patience is warranted. Using the cut-off of three con-
secutive rises at 3-month intervals in the volume of
mass-like consolidation as well as a two PET scans
showing a SUVmax of ≥ 5.0 both obtained at least 6
months after completion of SABR is a reasonable defin-
ition for tumor progression. Either of these findings
should warrant tissue confirmation with the caveat that
the sensitivity of biopsy is not known for certain. One
patient in a recent case series of surgical salvage follow-
ing SABR, for example required 11 biopsy attempts for
pathologic confirmation of recurrence [17].
Based on a recently published systemic review, a pro-
posed algorithm for imaging follow up of SABR patients
who are candidates for salvage treatment can be utilized
[18]. The patient presented here, if classified according
to that algorithm would have received the same ana-
tomic and functional imaging. Therefore, the algorithm
may serve as a framework to evaluate the optimal defini-
tions of recurrence after SABR. A patient cohort with a
greater number of treatment failures would be needed to
test this definition prior to being put into clinical prac-
tice, but in the current case, a potentially harmful biopsy
in a patient with limited underlying pulmonary function
may have been avoided.Conclusion
Current definitions of tumor recurrence after lung SABR
may overestimate the true incidence of progression. The
case presented here highlights the need to develop a
definition which incorporates anatomic, functional and
kinetic information to increase the diagnostic sensitivity
and specificity of tumor recurrence after lung SABR.
Stauder et al. Radiation Oncology 2013, 8:167 Page 5 of 5
http://www.ro-journal.com/content/8/1/167Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images.Competing interests
All authors declare that they have no competing interests.Authors’ contributions
MCS drafted the manuscript and conceived the report. JWR participated in
image acquisition and manuscript editing. MNW is the responsible clinic
physician and edited the manuscript. YIG is responsible for the technical
treatment design and follow-up recommendations on an institutional/
departmental level. KRO participated in coordination of clinical studies and
drafting of the manuscript. All authors have read and approved the final
manuscript.
Author details
1Department of Radiation Oncology, MD Anderson Cancer Center, 1515
Holcombe Blvd., Unit 1202, Houston 77030, TX, USA. 2Department of
Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Received: 11 February 2013 Accepted: 28 June 2013
Published: 6 July 2013References
1. Matsuo Y, Nagata Y, Mizowaki T, Takayama K, Sakamoto T, Sakamoto M,
Norihisa Y, Hiraoka M: Evaluation of mass-like consolidation after
stereotactic body radiation therapy for lung tumors. Int J Clin Oncol 2007,
12(5):356–362.
2. Takeda A, Kunieda E, Takeda T, Tanaka M, Sanuki N, Fujii H, Shigematsu N,
Kubo A: Possible Misinterpretation of Demarcated Solid Patterns of
Radiation Fibrosis on CT Scans as Tumor Recurrence in Patients
Receiving Hypofractionated Stereotactic Radiotherapy for Lung Cancer.
Int J Radiat Oncol Biol Phys 2008, 70(4):1057–1065.
3. Zhang X, Liu H, Balter P, Allen PK, Komaki R, Pan T, Chuang HH, Chang JY:
Positron Emission Tomography for Assessing Local Failure After
Stereotactic Body Radiotherapy for Non-Small-Cell Lung Cancer.
Int J Radiat Oncol Biol Phys 2012, 83(5):1558–1565.
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R,
Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation
criteria in solid tumours: Revised RECIST guideline (version 1.1).
Eur J Cancer 2009, 45(2):228–247.
5. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST:
Evolving Considerations for PET Response Criteria in Solid Tumors.
J Nucl Med 2009, 50(Suppl 1):122S–150S.
6. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA,
Pruim J, Price P: Measurement of clinical and subclinical tumour response
using [18F]-fluorodeoxyglucose and positron emission tomography:
review and 1999 EORTC recommendations. Eur J Cancer 1999,
35(13):1773–1782.
7. Stauder MC, Macdonald OK, Olivier KR, Call JA, Lafata K, Mayo CS, Miller RC,
Brown PD, Bauer HJ, Garces YI: Early pulmonary toxicity following lung
stereotactic body radiation therapy delivered in consecutive daily
fractions. Radiother Oncol 2011, 99(2):166–171.
8. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall
P, Lovelock M, Meeks S, Papiez L, et al: Stereotactic body radiation
therapy: the report of AAPM Task Group 101. Medical physics 2010,
37(8):4078–4101.
9. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N,
Ekberg L, Friesland S, Johansson K-A, et al: Outcome in a Prospective
Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer
Patients Treated With Stereotactic Body Radiotherapy. J Clin Oncol 2009,
27(20):3290–3296.
10. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA,
Timmerman R: Stereotactic Body Radiation Therapy for Early-Stage Non-
Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II
Study. Int J Radiat Oncol Biol Phys 2009, 75(3):677–682.11. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD: Stereotactic
body radiation therapy of early-stage non-small-cell lung carcinoma:
Phase I study. Int J Radiat Oncol Biol Phys 2005, 63(4):1010–1015.
12. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T,
Sakamoto M, Mitsumori M, Shibuya K, Araki N, et al: Clinical outcomes of a
phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions
for primary lung cancer using a stereotactic body frame. Int J Radiat
Oncol Biol Phys 2005, 63(5):1427–1431.
13. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A,
Bezjak A, Videtic G, Johnstone D, et al: Stereotactic Body Radiation
Therapy for Inoperable Early Stage Lung Cancer. JAMA-J Am Med Assoc
2010, 303(11):1070–1076.
14. Radiation Therapy Oncology Group: Lung Cancer Protocols. 0813 Phase I/II
SBRT. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?
action=openFile&FileID=9067 Accessed July 8, 2013.
15. Henderson MA, Hoopes DJ, Fletcher JW, Lin P-F, Tann M, Yiannoutsos CT,
Williams MD, Fakiris AJ, McGarry RC, Timmerman RD: A Pilot Trial of Serial
18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With
Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With
Hypofractionated Stereotactic Body Radiotherapy. Int J Radiat Oncol Biol
Phys 2010, 76(3):789–795.
16. Dunlap NE, Yang W, McIntosh A, Sheng K, Benedict SH, Read PW, Larner JM:
Computed tomography-based anatomic assessment overestimates local
tumor recurrence in patients with mass-like consolidation after
stereotactic body radiotherapy for early-stage non-small cell lung
cancer. Int J Radiat Oncol Biol Phys 2012, 84(5):1071–1077.
17. Allibhai Z, Cho BCJ, Taremi M, Atallah S, Hope A, Hwang D, Keshavjee S, Tsao
M, Yasufuku K, Kim S-W, et al: Surgical salvage following stereotactic body
radiotherapy for early-stage NSCLC. Eur Respir J 2012, 39(4):1039–1042.
18. Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt
RG, Palma DA: Radiographic changes after lung stereotactic ablative
radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A
systematic review of the literature. Radiother Oncol 2012, 102(3):335–342.
doi:10.1186/1748-717X-8-167
Cite this article as: Stauder et al.: Late tumor pseudoprogression
followed by complete remission after lung stereotactic ablative
radiotherapy. Radiation Oncology 2013 8:167.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
